iloprost   Click here for help

GtoPdb Ligand ID: 1895

Synonyms: Aurlumyn® | Ventavis®
Approved drug Immunopharmacology Ligand
iloprost is an approved drug (EMA (2003), FDA (2004))
Compound class: Synthetic organic
Comment: Iloprost is a synthetic analogue of PGI2.
Click here for help
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 4
Hydrogen bond donors 3
Rotatable bonds 8
Topological polar surface area 77.76
Molecular weight 360.23
XLogP 3.19
No. Lipinski's rules broken 0
Click here for help
Isomeric SMILES CC#CCC([C@@H](/C=C/C1[C@H](O)C[C@H]2[C@@H]1C/C(=C/CCCC(=O)O)/C2)O)C
InChI InChI=1S/C22H32O4/c1-3-4-7-15(2)20(23)11-10-18-19-13-16(8-5-6-9-22(25)26)12-17(19)14-21(18)24/h8,10-11,15,17-21,23-24H,5-7,9,12-14H2,1-2H3,(H,25,26)/b11-10+,16-8+/t15?,17-,18?,19-,20+,21+/m0/s1
No information available.
Summary of Clinical Use Click here for help
Iloprost is used to treat pulmonary arterial hypertension, scleroderma, Raynaud's phenomenon and ischemia. Aurlumyn® branded iloprost was FDA approved in February 2024, as a treatment to reduce the risk of digit amputations resulting from severe frostbite.
Mechanism Of Action and Pharmacodynamic Effects Click here for help
Iloprost binds with equal affinity to human prostanoid (IP1) and prostaglandin EP1 receptors. Clinically iloprost acts as a vasodilator, hypotensive, antidiuretic, and anti-coagulant. These properties ameliorate disease-associated pathology observed in the small pulmonary arteries of patients with pulmonary hypertension.
External links Click here for help